- Home
- ABEO vs ACHV Comparison
ABEO vs ACHV Comparison
Compare ABEO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEO | ACHV |
|---|---|---|
| Founded | 1974 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.2M | 231.0M |
| IPO Year | 1980 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABEO | ACHV |
|---|---|---|
| Price | $5.01 | $4.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $18.20 | $15.50 |
| AVG Volume (30 Days) | ★ 1.2M | 759.3K |
| Earning Date | 03-19-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,589.77 | N/A |
| P/E Ratio | $3.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $1.84 |
| 52 Week High | $7.54 | $6.03 |
Technical Indicators
Market Signals| Indicator | ABEO | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 40.19 |
| Support Level | $4.94 | $4.00 |
| Resistance Level | $5.26 | $4.47 |
| Average True Range (ATR) | 0.23 | 0.29 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 35.43 | 24.58 |
Price Performance
Historical ComparisonAbout ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.